Tivdak (tisotumab vedotin-tftv) / Genmab, Pfizer, Seagen, ZAI Lab  >>  Phase 2
Welcome,         Profile    Billing    Logout  

10 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tivdak (tisotumab vedotin-tftv) / Genmab, Pfizer
NCT03245736 / 2016-004743-37: Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Completed
2
5
Europe, US
Tisotumab Vedotin, TIVDAK
Seagen Inc., Genmab
Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer, Esophagus Cancer, Lung Cancer, Nonsmall Cell, Squamous Cell Carcinoma of the Head and Neck
01/19
01/19
innovaTV 204, NCT03438396 / 2017-003413-25: A Trial of Tisotumab Vedotin in Cervical Cancer

Checkmark Data from the InnovaTV 204 trial for recurrent or metastatic 2L cervical cancer at ESMO 2020
Sep 2020 - Sep 2020: Data from the InnovaTV 204 trial for recurrent or metastatic 2L cervical cancer at ESMO 2020
Checkmark Data from the InnovaTV 204 trial in patients with recurrent or metastatic 2L cervical cancer
Jun 2020 - Jun 2020: Data from the InnovaTV 204 trial in patients with recurrent or metastatic 2L cervical cancer
Completed
2
102
Europe, US, RoW
tisotumab vedotin, TIVDAK
Seagen Inc., Genmab, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgian Gynaecological Oncology Group, Gynecologic Oncology Group
Cervical Cancer
02/20
08/22
innovaTV 208, NCT03657043 / 2019-001219-22: A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in

Hourglass Sep 2021 - Dec 2021 : From innovaTV 208 trial for ovarian cancer
Completed
2
98
Europe, US
tisotumab vedotin, TIVDAK
Seagen Inc., Genmab
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
02/22
02/22
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Recruiting
2
692
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
04/25
11/26
innovaTV 202, NCT02552121 / 2015-001120-29: Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Completed
1/2
33
Europe, US
Tisotumab vedotin (HuMax-TF-ADC)
Seagen Inc., Genmab
Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer (CRPC), Esophagus Cancer, Lung Cancer (NSCLC)
12/17
12/17
2017-004758-40: Efficacy and safety of tisotumab vedotin (HuMax®-TF-ADC) monotherapy in combination in recurrent or Stage IVB cervical cancer

Ongoing
1/2
140
Europe, RoW
Tisotumab vedotin, HuMax®-TF-ADC, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Keytruda, Carboplatin, Avastin
Genmab A/S, GENMAB A/S, Genmab A/S
recurrent or stage IVB cervical cancer, cervical cancer, Diseases [C] - Cancer [C04]
 
 
2013-001074-15: First-in-human, dose-escalating safety study of tissue factor specific antibody drug conjugate tisotumab vedotin (HuMax®-TF-ADC) in patients with locally advanced and/or metastatic solid tumors known to express tissue factor

Completed
1/2
217
Europe
HuMax®-TF-ADC, IgG1-1015-011-1006, Powder for concentrate for solution for infusion
Genmab A/S, Genmab A/S
Cancer of the ovary, cervix, endometrium, bladder, prostate (castration-resistant prostate cancer [CRPC]), head and neck (squamous cell carcinoma of the head and neck [SCCHN]), esophagus or lung (non-small cell lung cancer [NSCLC], Cancers of the ovary, cervix, endometrium, bladder, prostate, head and neck, esophagus or lung, Diseases [C] - Cancer [C04]
 
 
innovaTV 201, NCT02001623: Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Checkmark Data from the InnovaTV 201 trial in patients with recurrent and/or metastatic cervical cancer
Oct 2018 - Oct 2018: Data from the InnovaTV 201 trial in patients with recurrent and/or metastatic cervical cancer
Completed
1/2
195
Europe, US
Tisotumab Vedotin (HuMax-TF-ADC), TIVDAK
Seagen Inc., Genmab
Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer (CRPC), Esophagus Cancer, Lung Cancer(NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN)
05/19
05/19
innovaTV 206, NCT03913741: A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies

Completed
1/2
23
Japan
tisotumab vedotin
Genmab, Seagen Inc.
Solid Tumor
08/20
10/21
KEYNOTE-834, NCT03786081 / 2017-004758-40: Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Active, not recruiting
1/2
214
Europe, US, RoW
Tisotumab Vedotin, TIVDAK, Bevacizumab, Avastin, Pembrolizumab, KEYTRUDA®, Carboplatin, Paraplatin
Seagen Inc., Genmab, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgian Gynaecological Oncology Group, GOG Foundation, Merck Sharp & Dohme LLC
Cervical Cancer
12/24
12/24

Download Options